<?xml version='1.0' encoding='utf-8'?>
<document id="21726496"><sentence text="Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults."><entity charOffset="56-68" id="DDI-PubMed.21726496.s1.e0" text="theophylline" /><entity charOffset="73-84" id="DDI-PubMed.21726496.s1.e1" text="roflumilast" /><pair ddi="false" e1="DDI-PubMed.21726496.s1.e0" e2="DDI-PubMed.21726496.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21726496.s1.e0" e2="DDI-PubMed.21726496.s1.e1" /></sentence><sentence text="To investigate whether a pharmacokinetic drug-drug interaction exists between theophylline (THEO), a CYP1A2 substrate with a narrow therapeutic index, and the concomitant substrate roflumilast (ROF), a novel selective PDE4 inhibitor partially metabolized by CYP1A2"><entity charOffset="78-90" id="DDI-PubMed.21726496.s2.e0" text="theophylline" /><entity charOffset="92-96" id="DDI-PubMed.21726496.s2.e1" text="THEO" /><entity charOffset="181-192" id="DDI-PubMed.21726496.s2.e2" text="roflumilast" /><entity charOffset="194-197" id="DDI-PubMed.21726496.s2.e3" text="ROF" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e0" e2="DDI-PubMed.21726496.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e0" e2="DDI-PubMed.21726496.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e0" e2="DDI-PubMed.21726496.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e0" e2="DDI-PubMed.21726496.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e1" e2="DDI-PubMed.21726496.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e1" e2="DDI-PubMed.21726496.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e1" e2="DDI-PubMed.21726496.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e2" e2="DDI-PubMed.21726496.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21726496.s2.e2" e2="DDI-PubMed.21726496.s2.e3" /></sentence><sentence text="" /><sentence text="In an open-label, 2-period, crossover study, Treatment A (oral ROF 500 μg q"><entity charOffset="63-65" id="DDI-PubMed.21726496.s4.e0" text="ROF" /></sentence><sentence text="d" /><sentence text=" on Days 6 - 10 in addition to oral THEO 375 mg b"><entity charOffset="36-38" id="DDI-PubMed.21726496.s6.e0" text="THEO" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=" on Days 1 - 10) and treatment B (oral ROF 500 μg q"><entity charOffset="39-42" id="DDI-PubMed.21726496.s9.e0" text="ROF" /></sentence><sentence text="d" /><sentence text=" on Days 1 - 5) were administered consecutively in random order to each of 24 healthy adult subjects" /><sentence text=" Both periods were separated by a wash-out phase of at least 10 days" /><sentence text=" Plasma samples for pharmacokinetic evaluation (AUC, Cmax, t1/2, tmax) including percent peak-trough fluctuation (%PTF) of THEO were taken"><entity charOffset="123-125" id="DDI-PubMed.21726496.s13.e0" text="THEO" /></sentence><sentence text=" Point estimates and the 90% confidence interval of the geometric mean ratios were calculated for AUC and Cmax and descriptive statistics for other pharmacokinetic parameters" /><sentence text="" /><sentence text="Concomitant administration of ROF did not alter pharmacokinetics of THEO"><entity charOffset="68-71" id="DDI-PubMed.21726496.s16.e0" text="THEO" /><entity charOffset="30-33" id="DDI-PubMed.21726496.s16.e1" text="ROF" /><pair ddi="false" e1="DDI-PubMed.21726496.s16.e1" e2="DDI-PubMed.21726496.s16.e1" /><pair ddi="false" e1="DDI-PubMed.21726496.s16.e1" e2="DDI-PubMed.21726496.s16.e0" /></sentence><sentence text=" With coadministered THEO, only steady-state total exposure to ROF (AUC) was increased by 28% whereas other pharmacokinetic parameters (t1/2, Cmax, tmax) of ROF and of the active metabolite roflumilast-N-oxide (R-NO), its main contributor to the pharmacodynamic effects, remained unchanged"><entity charOffset="190-209" id="DDI-PubMed.21726496.s17.e0" text="roflumilast-N-oxide" /><entity charOffset="211-215" id="DDI-PubMed.21726496.s17.e1" text="R-NO" /><entity charOffset="21-24" id="DDI-PubMed.21726496.s17.e2" text="THEO" /><entity charOffset="63-66" id="DDI-PubMed.21726496.s17.e3" text="ROF" /><entity charOffset="157-160" id="DDI-PubMed.21726496.s17.e4" text="ROF" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e2" e2="DDI-PubMed.21726496.s17.e2" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e2" e2="DDI-PubMed.21726496.s17.e3" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e2" e2="DDI-PubMed.21726496.s17.e4" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e2" e2="DDI-PubMed.21726496.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e2" e2="DDI-PubMed.21726496.s17.e1" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e3" e2="DDI-PubMed.21726496.s17.e3" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e3" e2="DDI-PubMed.21726496.s17.e4" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e3" e2="DDI-PubMed.21726496.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e3" e2="DDI-PubMed.21726496.s17.e1" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e4" e2="DDI-PubMed.21726496.s17.e4" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e4" e2="DDI-PubMed.21726496.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e4" e2="DDI-PubMed.21726496.s17.e1" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e0" e2="DDI-PubMed.21726496.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21726496.s17.e0" e2="DDI-PubMed.21726496.s17.e1" /></sentence><sentence text="" /><sentence text="Neither ROF nor its main metabolite had any impact on the metabolism of the concomitant CYP1A2 substrate THEO in humans"><entity charOffset="105-107" id="DDI-PubMed.21726496.s19.e0" text="THEO" /><entity charOffset="8-10" id="DDI-PubMed.21726496.s19.e1" text="ROF" /><pair ddi="false" e1="DDI-PubMed.21726496.s19.e1" e2="DDI-PubMed.21726496.s19.e1" /><pair ddi="false" e1="DDI-PubMed.21726496.s19.e1" e2="DDI-PubMed.21726496.s19.e0" /></sentence><sentence text=" Though co-administration of THEO resulted in a minor increase (28%) in total ROF exposure, no safety or tolerability concerns and no altered total PDE4 inhibition of both ROF and R-NO, were observed"><entity charOffset="29-31" id="DDI-PubMed.21726496.s20.e0" text="THEO" /><entity charOffset="78-80" id="DDI-PubMed.21726496.s20.e1" text="ROF" /><entity charOffset="172-174" id="DDI-PubMed.21726496.s20.e2" text="ROF" /><entity charOffset="180-182" id="DDI-PubMed.21726496.s20.e3" text="R-NO" /><pair ddi="false" e1="DDI-PubMed.21726496.s20.e0" e2="DDI-PubMed.21726496.s20.e0" /><pair ddi="false" e1="DDI-PubMed.21726496.s20.e0" e2="DDI-PubMed.21726496.s20.e1" /><pair ddi="true" e1="DDI-PubMed.21726496.s20.e0" e2="DDI-PubMed.21726496.s20.e2" /><pair ddi="true" e1="DDI-PubMed.21726496.s20.e0" e2="DDI-PubMed.21726496.s20.e3" /><pair ddi="false" e1="DDI-PubMed.21726496.s20.e1" e2="DDI-PubMed.21726496.s20.e1" /><pair ddi="true" e1="DDI-PubMed.21726496.s20.e1" e2="DDI-PubMed.21726496.s20.e2" /><pair ddi="true" e1="DDI-PubMed.21726496.s20.e1" e2="DDI-PubMed.21726496.s20.e3" /><pair ddi="false" e1="DDI-PubMed.21726496.s20.e2" e2="DDI-PubMed.21726496.s20.e2" /><pair ddi="false" e1="DDI-PubMed.21726496.s20.e2" e2="DDI-PubMed.21726496.s20.e3" /></sentence><sentence text="" /></document>